kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human CD9 Protein, 2x250µg  

Recombinant human CD9 Protein, 2x250µg

Recombinant Human CD9 Protein (Ser 112 - Ile 195), produced in human 293 cells (HEK293), His tag

Recombinant human protein, IL2RB, RP5-1170K4.6, CD122, P70-75

More details


Availability: within 7 days

1 600,00 €

CD9 antigen also known as tetraspanin-29 (TSPAN29), 5H9 antigen, Leukocyte antigen MIC3 (MIC3), Motility-related protein, is a multi-pass membrane protein which belongs to the tetraspanin (TM4SF) family or the transmembrane 4 superfamily. CD9 is a cell surface glycoprotein that is known to complex with integrins and other transmembrane 4 superfamily proteins. TSPAN29 is found on the surface of exosomes. MIC3 Involved in platelet activation and aggregation, regulates paranodal junction formation and also Involved in cell adhesion, cell motility and tumor metastasis. CD9 antigen also seems to be a key part in the egg-sperm fusion during mammalian fertilization.

Human CD9, His Tag (CD9-H5220) is expressed from human 293 cells (HEK293). It contains AA Ser 112 - Ile 195 (Accession # P21926-1).
Predicted N-terminus: Ser 112

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 11.6 kDa. The protein migrates as 12 kDa under reducing (R) condition (SDS-PAGE).

Less than 1.0 EU per μg of the rhCD9 by the LAL method.

>95% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).


(1) Katz F., et al., 1984, Eur J Immunol 13 (12): 1008–1013.
(2) François Le Naour, 2000, Science 287 (5451): 319–321.
(3) Ikeyama S., et al., 1993, J. Exp. Med. 177:1231-1237.
(4) Masellis-Smith A., et al., 1994, J. Immunol. 152:2768-2777.
(5) Higginbottom A., et al., 2003, Biochem. Biophys. Res. Commun. 311:208-214.